Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?
- PMID: 34201542
- PMCID: PMC8306447
- DOI: 10.3390/medicina57070643
Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?
Abstract
Background and Objectives: Lactobacillus reuteri DSM 17938 (L. reuteri) is a probiotic that can colonize different human body sites, including primarily the gastrointestinal tract, but also the urinary tract, the skin, and breast milk. Literature data showed that the administration of L. reuteri can be beneficial to human health. The aim of this review was to summarize current knowledge on the role of L. reuteri in the management of gastrointestinal symptoms, abdominal pain, diarrhea and constipation, both in adults and children, which are frequent reasons for admission to the emergency department (ED), in order to promote the best selection of probiotic type in the treatment of these uncomfortable and common symptoms. Materials and Methods: We searched articles on PubMed® from January 2011 to January 2021. Results: Numerous clinical studies suggested that L. reuteri may be helpful in modulating gut microbiota, eliminating infections, and attenuating the gastrointestinal symptoms of enteric colitis, antibiotic-associated diarrhea (also related to the treatment of Helicobacter pylori (HP) infection), irritable bowel syndrome, inflammatory bowel disease, and chronic constipation. In both children and in adults, L. reuteri shortens the duration of acute infectious diarrhea and improves abdominal pain in patients with colitis or inflammatory bowel disease. It can ameliorate dyspepsia and symptoms of gastritis in patients with HP infection. Moreover, it improves gut motility and chronic constipation. Conclusion: Currently, probiotics are widely used to prevent and treat numerous gastrointestinal disorders. In our opinion, L. reuteri meets all the requirements to be considered a safe, well-tolerated, and efficacious probiotic that is able to contribute to the beneficial effects on gut-human health, preventing and treating many gastrointestinal symptoms, and speeding up the recovery and discharge of patients accessing the emergency department.
Keywords: Lactobacillus reuteri (DSM 17938); Limosilactobacillus reuteri; constipation; diarrhea; emergency department; probiotics.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Effect of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial.Eur J Pediatr. 2024 May;183(5):2311-2324. doi: 10.1007/s00431-024-05473-y. Epub 2024 Mar 1. Eur J Pediatr. 2024. PMID: 38427038 Clinical Trial.
-
Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms.Front Cell Infect Microbiol. 2023 Aug 18;13:1254198. doi: 10.3389/fcimb.2023.1254198. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37662007 Free PMC article. Review.
-
Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.Helicobacter. 2023 Dec;28(6):e13017. doi: 10.1111/hel.13017. Epub 2023 Aug 23. Helicobacter. 2023. PMID: 37614081 Clinical Trial.
-
Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial.Nutrients. 2020 Jan 15;12(1):225. doi: 10.3390/nu12010225. Nutrients. 2020. PMID: 31952280 Free PMC article. Clinical Trial.
-
Use of Limosilactobacillus reuteri DSM 17938 in paediatric gastrointestinal disorders: an updated review.Benef Microbes. 2022 Aug 3;13(3):221-242. doi: 10.3920/BM2021.0151. Epub 2022 Feb 25. Benef Microbes. 2022. PMID: 35212258 Review.
Cited by
-
The Gut Microbiome and Its Implication in the Mucosal Digestive Disorders.Biomedicines. 2022 Dec 2;10(12):3117. doi: 10.3390/biomedicines10123117. Biomedicines. 2022. PMID: 36551874 Free PMC article. Review.
-
Electroacupuncture alleviates functional constipation by upregulating host-derived miR-205-5p to modulate gut microbiota and tryptophan metabolism.Front Microbiol. 2025 Feb 5;16:1517018. doi: 10.3389/fmicb.2025.1517018. eCollection 2025. Front Microbiol. 2025. PMID: 39973939 Free PMC article.
-
Survival and Interplay of γ-Aminobutyric Acid-Producing Psychobiotic Candidates with the Gut Microbiota in a Continuous Model of the Human Colon.Biology (Basel). 2022 Sep 4;11(9):1311. doi: 10.3390/biology11091311. Biology (Basel). 2022. PMID: 36138790 Free PMC article.
-
Probiotic Bacteria from Human Milk Can Alleviate Oral Bovine Casein Sensitization in Juvenile Wistar Rats.Microorganisms. 2023 Apr 14;11(4):1030. doi: 10.3390/microorganisms11041030. Microorganisms. 2023. PMID: 37110453 Free PMC article.
-
Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection.Pathogens. 2024 Nov 21;13(12):1028. doi: 10.3390/pathogens13121028. Pathogens. 2024. PMID: 39770288 Free PMC article. Review.
References
-
- Kubota M., Ito K., Tomimoto K., Kanazaki M., Tsukiyama K., Kubota A., Kuroki H., Fujita M., Vandenplas Y. Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial. Nutrients. 2020;12:225. doi: 10.3390/nu12010225. - DOI - PMC - PubMed
-
- Ojetti V., Petruzziello C., Migneco A., Gnarra M., Gasbarrini A., Franceschi F. Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: A retrospective study. Eur. Rev. Med. Pharmacol. Sci. 2017;21:1702–1708. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous